NEW YORK, NY / ACCESSWIRE / October 31, 2017 / U.S. markets saw a mixed Monday as health-care and consumer-staples stocks slumped, dragging down the Dow Jones and S&P 500, while the technology sector extended gains in early trading Monday lifting the Nasdaq to a new intra-day record. The Dow Jones Industrial Average declined 0.36 percent to close at 23,348.74, while the S&P 500 Index fell 0.32 percent to close at 2,572.83. The Nasdaq Composite Index hit a high of 6,727.39 before settling to close at 6,698.96, a decrease of 0.03 percent. Corporate earnings remain a key focus for investors. As of Friday, more than 50 percent of the S&P 500 Index has reported earnings, with 76 percent of them topping estimates on the bottom line and 67 percent of them topping sales expectations, according to FactSet.
RDI Initiates Coverage on:
Valeant Pharmaceuticals Intl Inc.
Intrexon Corporation stock moved 1.84% lower Monday, to close the day at $16.58. The stock recorded a trading volume of 1,033,448 shares, which was above its three months average volume of 975,315 shares. In the last year, Intrexon Corporation shares have traded in a range of 16.11 - 32.9. The share price has gained 2.92% from its 52-week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $18.61 is greater than its 200-day moving average of $20.92. Shares of Intrexon Corporation have fallen approximately 31.77 percent year-to-date.
Access RDI's Intrexon Corporation Research Report at:
On Monday, shares in Valeant Pharmaceuticals recorded a trading volume of 8,661,235 shares, which was below the three months average volume of 11,764,200 shares. The stock ended the day flat at 11.41. The share price has gained 37.29% from its 52-week low with a 52-week trading range of 8.31 - 24.30. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $13.60 is below its 200-day moving average of $13.67. Shares of Valeant Pharmaceuticals have fallen approximately 21.42 percent year-to-date.
Access RDI's Valeant Pharmaceuticals Intl Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.